349097-66-1

Basic information

• Product Name: 3-CHLORO-N-(2-FLUOROPHENYL)PROPANAMIDE
• Synonyms: 3-CHLORO-N-(2-FLUOROPHENYL)PROPANAMIDE;3-CHLORO-N-(2-FLUORO-PHENYL)-PROPIONAMIDE;3-chloro-N-(2-fluorophenyl)propanamide(SALTDATA: FREE)
• CAS NO: 349097-66-1
• Molecular Formula: C₉H₉ClFNO
• Molecular Weight: 201.63
• Mol File: 349097-66-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 346.4°C at 760 mmHg
• Flash Point: 163.3°C
• Appearance: /
• Density: 1.304g/cm³
• Vapor Pressure: 5.77E-05mmHg at 25°C
• Refractive Index: 1.56
• CAS DataBase Reference: 3-CHLORO-N-(2-FLUOROPHENYL)PROPANAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CHLORO-N-(2-FLUOROPHENYL)PROPANAMIDE(349097-66-1)
• EPA Substance Registry System: 3-CHLORO-N-(2-FLUOROPHENYL)PROPANAMIDE(349097-66-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 349097-66-1(Hazardous Substances Data)

Usage

General Description

3-CHLORO-N-(2-FLUOROPHENYL)PROPANAMIDE, also known as LORNOXICAM, is a chemical compound that belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs). It is commonly used to relieve pain, inflammation, and stiffness caused by conditions such as arthritis. LORNOXICAM works by blocking the production of certain natural substances in the body that cause pain and inflammation. It is usually administered orally in the form of tablets or capsules and is generally well-tolerated, but may cause side effects such as stomach upset, dizziness, and headache. It is important to use LORNOXICAM only as directed by a healthcare professional and to discuss potential risks and benefits before starting treatment.

InChI:InChI=1/C9H9ClFNO/c10-6-5-9(13)12-8-4-2-1-3-7(8)11/h1-4H,5-6H2,(H,12,13)

Upstream product

• 348-54-9 2-Fluoroaniline 
• 625-36-5 2-chloropropionyl chloride 

Downstream Products

• 143268-79-5 8-fluoro-3,4-dihydro-1H-quinolin-2-one 
• 1404367-02-7 9-fluoro-1-methyl-7-(5-phenyl-pyridin-3-yl)-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline 

Relevant articles and documents

Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a ]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability

CYP11B2 inhibition is a promising treatment for diseases caused by excessive aldosterone. To improve the metabolic stability in human liver miscrosomes of previously reported CYP11B2 inhibitors, modifications were performed via a combination of ligand-and

NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12/

NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, R7, R8, R9, R10, R11, R12/